Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes - Poll - MDSpire

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

  • By

  • Abiola Bolarinwa

  • Madhu Nagaraj

  • Saurabh Zanwar

  • Nadine Abdallah

  • P. Leif Bergsagel

  • Moritz Binder

  • Francis Buadi

  • Saurabh Chhabra

  • Joselle Cook

  • David Dingli

  • Angela Dispenzieri

  • Morie A. Gertz

  • Wilson Gonsalves

  • Suzanne Hayman

  • Prashant Kapoor

  • Taxiarchis Kourelis

  • Nelson Leung

  • Yi Lin

  • Eli Muchtar

  • Ricardo Parrondo

  • Vivek Roy

  • Taimur Sher

  • Mustaqeem Siddiqui

  • Rahma Warsame

  • Amie Fonder

  • Miriam Hobbs

  • Yi Lisa Hwa

  • Michelle Rogers

  • Udit Yadav

  • J. Erin Wiedmeier-Nutor

  • Linda B. Baughn

  • S. Vincent Rajkumar

  • Rafael Fonseca

  • Sikander Ailawadhi

  • Shaji Kumar

  • April 4, 2025

  • 0 min

Share

Original Source(s)

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

  • by Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, Nadine Abdallah, P. Leif Bergsagel, Moritz Binder, Francis Buadi, Saurabh Chhabra, Joselle Cook, David Dingli, Angela Dispenzieri, Morie A. Gertz, Wilson Gonsalves, Suzanne Hayman, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Yi Lin, Eli Muchtar, Ricardo Parrondo, Vivek Roy, Taimur Sher, Mustaqeem Siddiqui, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Michelle Rogers, Udit Yadav, J. Erin Wiedmeier-Nutor, Linda B. Baughn, S. Vincent Rajkumar, Rafael Fonseca, Sikander Ailawadhi, Shaji Kumar

  • April 4, 2025

Related Content

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease